Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Zhejiang Provincial People's Hospital

Status

Not yet enrolling

Conditions

Glioblastoma Multiforme (GBM)

Treatments

Procedure: GBM patients recevied traditional treatment options

Procedure: Photodynamic therapy (PDT)

Study type

Observational

Funder types

Other

Identifiers

NCT06939400

KY2024208

Details and patient eligibility

About

GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.

Exclusion criteria

Photosensitizer allergy.
- Severe coagulation disorder.
  - Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
    - Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.

Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.